Hester Bios

Who are the top shareholders of the Hester Bios?

The top shareholders of Hester Bios include promoter Rajiv Dinesh Gandhi with 10.47% ownership, while public shareholder Kuntal Hasmukhlal Shah holds 3.17%. Individual investors own 32.64%, and foreign institutional investors hold 0.87%.

The top shareholders of Hester Bios include the promoters, with Rajiv Dinesh Gandhi being the promoter with the highest holding at 10.47%. The company has no pledged promoter holdings. In terms of public shareholders, Kuntal Hasmukhlal Shah holds the highest stake at 3.17%. Additionally, individual investors collectively hold 32.64% of the shares. There are also 20 foreign institutional investors (FIIs) who hold a total of 0.87%, and mutual funds are represented by two schemes, holding 0.0%.

how big is Hester Bios?

As of Jun 06, Hester Biosciences Ltd has a market capitalization of 1,582.28 Cr, with net sales of 311.11 Cr and a net profit of 27.49 Cr reported for the latest four quarters. Shareholder's funds are 291.79 Cr, and total assets amount to 662.35 Cr as of Mar'24.

Market Cap: As of Jun 06, Hester Biosciences Ltd has a market capitalization of 1,582.28 Cr, which classifies it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Hester Biosciences Ltd reported net sales of 311.11 Cr and a net profit of 27.49 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: The balance sheet data is consolidated and pertains to the latest annual period ending in Mar'24. Shareholder's funds are reported at 291.79 Cr, while total assets amount to 662.35 Cr.

What does Hester Bios do?

Hester Biosciences Ltd is a leading Indian animal healthcare company, incorporated in 1987, with a market cap of Rs 1,600 Cr and reported net sales of 82 Cr and net profit of 1 Cr for Q1 2025. Key financial metrics include a P/E ratio of 57.00 and a return on equity of 8.75%.

Overview: <BR>Hester Biosciences Ltd is a leading animal healthcare company in India, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap firm.<BR><BR>History: <BR>The company was incorporated in April 1987 and has been engaged in its current operations since then. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 82 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 1,600 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 57.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.32% <BR>Debt Equity: 0.66 <BR>Return on Equity: 8.75% <BR>Price to Book: 5.03<BR><BR>Contact Details: <BR>Address: 1st Flr PushpakPachvati Circle, Motilal Hirabhai Road Ahmedabad Gujarat : 380006 <BR>Tel: 91-079-26445107 <BR>Fax: 91-079-26445105 <BR>Email: mail@hester.in <BR>Website: http://www.hester.in

Who are in the management team of Hester Bios?

As of March 2023, the management team of Hester Bios includes Bhupendra V Gandhi (Chairman), Rajiv D Gandhi (CEO), and several other executive and non-executive directors, totaling eleven members with a mix of independent and non-independent roles.

As of March 2023, the management team of Hester Bios includes the following individuals:<BR><BR>1. Bhupendra V Gandhi - Chairman & Non Executive Director<BR>2. Sanjiv D Gandhi - Non-Executive & Non-Independent Director<BR>3. Nina Gandhi - Non Executive Director<BR>4. Sandhya Patel - Independent Non Executive Director<BR>5. Ashok Bhadakal - Independent Non Executive Director<BR>6. Ameet Desai - Independent Non Executive Director<BR>7. Rajiv D Gandhi - Executive Director, Managing Director, CEO, and Promoter<BR>8. Ravin Gandhi - Non-Executive & Non-Independent Director<BR>9. Priya Rajiv Gandhi - Executive Director<BR>10. Anil Jain - Independent Non Executive Director<BR>11. Jatin Yagneshbhai Trivedi - Independent Non Executive Director<BR><BR>This diverse team includes a mix of executive and non-executive members, with several independent directors contributing to the governance of the company.

What is the bonus history of the Hester Bios?

Hester Biosciences Ltd announced a 1:2 bonus issue on September 27, 2012, with a record date of September 29, 2012, meaning shareholders received one additional share for every two shares held.

Hester Biosciences Ltd has a bonus history that includes a 1:2 bonus issue announced on September 27, 2012. The record date for this bonus was September 29, 2012. This means that for every two shares held, shareholders received one additional share as a bonus. If you have any more questions about Hester Bios or need further details, feel free to ask!

Has Hester Bios declared dividend?

Hester Biosciences Ltd has declared a 60% dividend, amounting to ₹6 per share, with an ex-date of August 22, 2024. While the company shows mixed total returns over various periods, it has experienced significant declines in the short term but positive returns over the longer term.

Hester Biosciences Ltd has declared a 60% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 60%<BR>- Amount per share: 6<BR>- Ex-date: 22 Aug 24<BR><BR>Dividend Yield: 0.32%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -25.97%, the dividend return was 0%, resulting in a total return of -25.97%.<BR><BR>Over the past year, the price return was 4.14%, with a dividend return of 0.32%, leading to a total return of 4.46%.<BR><BR>In the 2-year period, the price return was 14.47%, the dividend return was 0.86%, culminating in a total return of 15.33%.<BR><BR>For the 3-year period, the price return was -18.58%, the dividend return was 1.15%, which resulted in a total return of -17.43%.<BR><BR>In the last 4 years, the price return was -29.74%, with a dividend return of 1.29%, leading to a total return of -28.45%.<BR><BR>Over the 5-year period, the price return was 47.13%, the dividend return was 3.36%, resulting in a total return of 50.49%.<BR><BR>Overall, Hester Biosciences Ltd has declared a significant dividend, but the total returns over various periods show mixed performance, with notable declines in the short term and positive returns over the longer term.

Who are the peers of the Hester Bios?

Hester Bios' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Bliss GVS Pharma, Themis Medicare, Lincoln Pharma, and Anuh Pharma. Hester Bios has average management risk, below average growth, and a 1-year return of -0.36%, outperforming only Themis Medicare.

Peers: The peers of Hester Bios are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Bliss GVS Pharma, Themis Medicare, Lincoln Pharma., and Anuh Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while Average management risk is found at Hester Bios, Bliss GVS Pharma, Themis Medicare, Lincoln Pharma., Anuh Pharma, and the rest. Growth is Excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while Below Average growth is noted at Divi's Lab., Torrent Pharma, Hester Bios, Bliss GVS Pharma, Themis Medicare, Lincoln Pharma., and the rest. Capital Structure is Excellent at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Bliss GVS Pharma, Lincoln Pharma., and Anuh Pharma, while Below Average Capital Structure is seen at Hester Bios.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Themis Medicare at -33.90%. Hester Bios has a 1-year return of -0.36%, which is higher than Themis Medicare but lower than most peers. Additionally, the six-month return is negative for Themis Medicare, Lincoln Pharma., and Hester Bios.

Is Hester Bios overvalued or undervalued?

As of April 1, 2025, Hester Bios is considered overvalued with a very expensive valuation grade, reflected in its high PE ratio of 57.23 and EV to EBITDA ratio of 29.14, despite a recent stock return of 15.37% that outperformed the Sensex, while its long-term performance has underperformed the index.

As of 1 April 2025, Hester Bios has moved from an expensive to a very expensive valuation grade. The company is currently considered overvalued. Key ratios include a PE ratio of 57.23, an EV to EBITDA ratio of 29.14, and a Price to Book Value of 5.01. In comparison to its peers, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Divi's Lab shows a significantly higher PE ratio of 79.33 and an EV to EBITDA of 57.35, indicating that Hester Bios is trading at a premium relative to some peers.<BR><BR>Despite a recent stock return of 15.37% over the past month, which outperformed the Sensex's 3.87%, the long-term performance shows that Hester Bios has underperformed the index year-to-date and over three years. This suggests that the current valuation may not be justified given the company's inconsistent performance relative to both its peers and the broader market.

How has been the historical performance of Hester Bios?

Hester Bios has shown steady growth in net sales and profitability, with net sales increasing from INR 178.07 crore in March 2019 to INR 311.10 crore in March 2025, and profit after tax rising from INR 16.56 crore to INR 24.73 crore in the same period, despite some fluctuations in expenses and cash flow. Total assets and liabilities decreased slightly, while cash flow from operating activities improved significantly.

Answer:<BR>The historical performance of Hester Bios shows a steady growth in net sales and profitability over the years, with some fluctuations in specific metrics.<BR><BR>Breakdown:<BR>Hester Bios has demonstrated a consistent increase in net sales from INR 178.07 crore in March 2019 to INR 311.10 crore in March 2025. Total operating income has followed a similar trend, reaching INR 311.10 crore in March 2025, up from INR 266.09 crore in March 2023. The company's total expenditure, excluding depreciation, was INR 250.05 crore in March 2025, slightly down from INR 250.90 crore in March 2024. Operating profit (PBDIT) has shown resilience, with a figure of INR 64.97 crore in March 2025, compared to INR 64.29 crore in March 2024. Profit before tax was INR 35.47 crore in March 2025, an increase from INR 27.34 crore in March 2024, while profit after tax rose to INR 24.73 crore from INR 16.56 crore in the previous year. The company's total assets were INR 653.38 crore in March 2025, a decrease from INR 662.35 crore in March 2024, and total liabilities also decreased to INR 653.38 crore from INR 662.35 crore. Cash flow from operating activities improved significantly to INR 64.00 crore in March 2025 from INR 48.00 crore in March 2024, while net cash outflow was recorded at INR -6.00 crore in March 2025. Overall, Hester Bios has shown a positive trajectory in sales and profitability, despite some fluctuations in expenses and cash flow.

Are Hester Bios latest results good or bad?

Hester Biosciences' latest results show a significant profit increase of 76.22% year-on-year, but declining net sales and operating margins indicate underlying operational challenges. While profits appear strong, reliance on extraordinary income raises concerns about sustainability.

Hester Biosciences' latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹14.45 crores for Q2 FY26, which is a significant increase of 76.22% year-on-year. This improvement in profitability is noteworthy, especially considering the profit margin (PAT margin) has risen to 20.19%, up from 10.03% a year ago.<BR><BR>However, the underlying operational performance raises concerns. Net sales for the quarter fell to ₹70.97 crores, marking a decline of 15.20% year-on-year and a more pronounced 15.62% drop from the previous quarter. Additionally, the operating margin (excluding other income) decreased to 16.50%, down from 22.89% in the same quarter last year, indicating challenges in the core business operations.<BR><BR>A significant portion of the profit increase is attributed to extraordinary other income, which accounted for 57.10% of profit before tax. This reliance on non-operating income raises questions about the sustainability of the profit levels moving forward.<BR><BR>In summary, while the profit figures may seem positive at first glance, the decline in sales and operating margins suggests that the company is facing significant challenges in its core business. Therefore, the overall assessment of Hester Biosciences' latest results leans towards caution, highlighting both the potential for profitability and the underlying operational difficulties.

Should I buy, sell or hold Hester Bios?

Is Hester Bios technically bullish or bearish?

As of November 24, 2025, Hester Bios is in a strong bearish trend, indicated by bearish MACD readings, moving averages, and KST across multiple time frames, despite a mildly bullish signal from Dow Theory on the weekly chart.

As of 24 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Hester Bios is bearish with a strong indication. Key indicators driving this stance include bearish MACD readings on both weekly and monthly time frames, bearish moving averages on the daily chart, and a bearish KST on both weekly and monthly levels. The Bollinger Bands also reflect a bearish trend on the weekly chart and a mildly bearish stance on the monthly chart. Although Dow Theory shows a mildly bullish signal on the weekly, the overall bearish indicators dominate the analysis.

When is the next results date for Hester Biosciences Ltd?

The next results date for Hester Biosciences Ltd is January 30, 2026.

The next results date for Hester Biosciences Ltd is scheduled for January 30, 2026.

Why is Hester Biosciences Ltd falling/rising?

As of 28-Jan, Hester Biosciences Ltd's stock price is rising, currently at 1,433.10, reflecting a short-term gain despite a year-to-date decline of 9.98% and a significant drop of 31.72% over the past year, indicating caution due to weak long-term fundamentals.

As of 28-Jan, Hester Biosciences Ltd's stock price is rising, currently at 1,433.10, reflecting an increase of 32.8 (2.34%). This upward movement is supported by the stock outperforming its sector by 1.86% today and achieving a consecutive gain over the last two days, with a total return of 3.73% during this period. Additionally, the stock reached an intraday high of Rs 1439.2, marking a 2.78% increase.<BR><BR>Despite this recent positive performance, the stock has shown a decline over longer periods, with a year-to-date decrease of 9.98% and a significant drop of 31.72% over the past year. The stock's performance has also been below that of the Sensex, which has increased by 8.49% over the same year. <BR><BR>Factors contributing to the stock's rise today include its higher performance relative to the sector and a solid operating cash flow of Rs 64.51 Cr, alongside a favorable debt-equity ratio of 0.63 times. However, the overall long-term outlook remains weak, with a negative compound annual growth rate (CAGR) of -0.36% in operating profits over the last five years and a high debt to EBITDA ratio of 3.73 times, indicating challenges in servicing debt.<BR><BR>In summary, while Hester Biosciences Ltd is experiencing a short-term rise in stock price, the long-term fundamentals suggest caution due to significant past underperformance and weak growth indicators.

Which are the latest news on Hester Bios?